search
Back to results

Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia

Primary Purpose

Schizophrenia

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
endurance training
balance and tone program
Sponsored by
Ludwig-Maximilians - University of Munich
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Schizophrenia focused on measuring exercise

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Informed consent given by the subject; DSM-IV-TR diagnosis of schizophrenic psychosis (295.10-30, 295.90); age 18 to 65 years, male or female; PANSS at baseline: total score ≤ 75, proper contraception in female patients of childbearing potential; treatment with one or two antipsychotics in a stable dose of at least two weeks, body mass index between 18 and 40.

Exclusion Criteria:

  • Lack of accountability; positive urine drug-screening for illicit drugs at screening (except benzodiazepines); serious suicidal risk at screening visit; other relevant interferences of axis 1 according to diagnostic evaluation (MINI); other relevant neurological or other medical disorders; pregnancy or lactation.

Sites / Locations

  • Ludwig-Maximilians-University of Munich

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

endurance training

balance and tone program

Arm Description

endurance training with stationary bicycles

flexibility, core strength, balance, relaxation

Outcomes

Primary Outcome Measures

all-cause discontinuation
Reason of study discontinuation will be identified. The all-cause-discontinuation questionnaire will be called up 9 times from baseline up to 12 months (compare time frame) including 26 weeks of intervention and 26 weeks follow up period. Reasons are defined as (1) relevant worsening of clinical symptoms (PANSS total score above 75 on cancerous visits for more than 14 days. (2) failure to take the prescribed medication for more than 14 days. (3) Failure to comply scheduled study or diagnostic appointments for more than 6 weeks (4) Patient unavailability despite extensive efforts of the treatment team (5) Withdrawal of patient consent (6) Clinician discontinuation.

Secondary Outcome Measures

improvement in neurocognition (VLMT)
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Verbal Learning and Memory Test (VLMT).
improvement in neurocognition (DSST)
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using a test of verbal declarative episodic memory, the Digit Symbol Substitution Test (DSST).
improvement in neurocognition (TMT)
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Trail Making Test A and B (TMT) as a test of executive functions, quick visual comprehension, attention, and processing speed.
improvement in neurocognition (B-CATS)
The partial aspect of verbal fluid from the letter Cognitive Assessment Tool for Schizophrenia (B-CATS) is also used in the neuropsychological investigation at the main measurement times (at baseline, day 98, day 182 and day 365).
improvement in neurocognition (MASC)
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Facial Affect Recognition (AOP) and Theory of Mind methods. These are tasks using the Movie for the Assessment of Social Cognition (MASC).
improvement in psychopathology (PANSS)
The assessment of psychopathology on the basis of a patient interview takes place at all main measurement times. At baseline, day 98, 182 and day 365. The PANSS uses a standard procedure for assessing schizophrenia symptoms, which measures the severity of individual symptoms as well as the various symptom subgroups of positive and negative symptoms and general psychopathology.
improvement in psychopathology (CGI)
The Clinical Global Impression Scale (CGI) assesses the overall symptom severity and response to interventions or therapies for psychiatric conditions to assess the effectiveness of the measures applied. It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.
improvement in psychopathology (SOFAS)
The Social and Occupational Functioning Assessment Scale (SOFAS) estimates social and professional performance. It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.
improvement in psychopathology (GAF)
The Social Assessment of Functioning Scale (GAF) also estimates social and professional performance. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
improvement in psychopathology (BSI-53)
The Brief Symptom Inventory (BSI-53) records the symptoms using 53 items. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
improvement in psychopathology (CDSS)
The Calgary Depression Scale for Schizophrenia (CDSS) measures suicidality and severity of depressive symptoms. It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.
improvement in social and occupational functioning (UPSA-B)
The University of California San Diego Performance-based Skills Assessment (UPSA-B) will be used to assess the day-to-day functioning of patients with schizophrenia in the household, communications, finance, transportation, and leisure activities role play situations. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
improvement in social and occupational functioning (FROGS)
Functional Remission of General Schizophrenia (FROGS) is used as a tool to measure changes in functional levels. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
improvement in social and occupational functioning (PSP)
The Personal and Social Performance Scale (PSP) is also a tool to measure changes in functional levels. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
improvement in quality of life
Only at the beginning and end of the intervention, and after one year, is the World Health Organization's Quality of Life Questionnaire (WHOQOL-Bref) used to record quality of life (The WHOQOL Group, 1998).
improvement in body mass index (BMI)
Also, the body height (in meter) and weight (in kg) of the study participants are measured. Thereupon the BMI is calculated from the body weight (kg) divided by the square of the height (m2). The unit of BMI is kg / m2.
change of connectivity analysis (MRI of the brain)
At four time points, just prior to initiation of V1, V4, V6 after the end of the intervention and at V9 after the follow-up period of 6 months, structural and functional MRI (fMRI) examinations are performed on a 3 Tesla whole-body MR scanner in patients and healthy control subjects (Siemens) made. The findings are compared with data from healthy controls and non-diseased first-degree relatives of patients with schizophrenia who have been evaluated in other BMBF-funded studies ("MooDS", "IntegraMent"). In addition, cross-sectional comparisons (TAU + Exercise vs. TAU + BKGT) and progress measurements to characterize treatment effects are planned. The measurements are divided into 2 appointments to reduce the burden on patients and subjects by the measurement time.
change of volumes of brain regions (MRI)
First, structural measurements (T1 sequence, duration: approx. 5 minutes) and investigations of the fiber connections in the brain by means of diffusion-weighted imaging (DTI, duration: approx. 10 minutes) are carried out.
change of brain function (MRI)
By means of fMRI, the tasks resting activity, working memory, episodic memory, reward processing, social perspective takeover, emotion processing as well as ability to inhibit are to be investigated with already well pre-examined tasks. A function measurement is performed at rest without stimulation (rsMRT), which provides information on the functional networking of different brain regions at rest (duration: approx. 5 minutes). There are also three fMRI surveys that record brain activity during simple psychological tasks. - The ability to inhibit (prefrontal cortex, anterior cingulate gyrus) is examined by means of a so-called flanker task. This is to respond to a specific target stimulus, which is surrounded by either the same (congruent) or by distracting (incongruent) stimuli. - Duration: 11 minutes
improvement of endurance capacity
As part of the sports medical stress test, the determination of endurance performance in patients and control subjects takes place. For this examination, like in training, finder bike use and measurements of heart rate, lactate concentration and exertion sensation are performed. The ergometry is carried out as a Vita maxima examination, so it ends when the subjects can not or do not want to keep pedaling or when the termination criteria according to Steinacker & Liu (2002) occur. From the examination, various submaximal and maximal parameters can be determined, have the validity for endurance performance and the training intensity can be determined. The examination is carried out under standardized and safe conditions and after a detailed medical history and physical examination to exclude contraindications. Activity meters are used to control the physical activity of study participants outside the study intervention.
change of medication and attitude of the study participants to therapy (DAI)
Also, the attitude of the study participants to therapy and medication is recorded. For this, the Drug Attitude Inventory (DAI) is used. Is takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
change of medication and attitude of the study participants to therapy (SES)
The Service Engagement Scale (SES), which assesses accessibility, cooperation, help seeking and adherence, is used. It takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
improvement in metabolic parameters
The laboratory diagnostic measures include a laboratory blood test, with evaluation of blood lipid levels, the C-reactive protein, glycohemoglobin (HBA1c). It takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
urine (testing pregnancy and drug abuse)
Examination of the urine at baseline excludes pregnancy and drug abuse.
gene expression
Investigation of gene expression takes place at baseline.
change of genome-wide epigenetics
Investigation of genome-wide epigenetics takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
change of proteomics
Investigation of proteomics at the main measurement times (at baseline, day 98, day 182 and day 365).
change of BDNF level
Investigation of BDNF levels at the main measurement times (at baseline, day 98, day 182 and day 365).

Full Information

First Posted
February 19, 2018
Last Updated
February 15, 2022
Sponsor
Ludwig-Maximilians - University of Munich
Collaborators
RWTH Aachen University, Charite University, Berlin, Germany, Heinrich-Heine University, Duesseldorf, Central Institute of Mental Health, Mannheim
search

1. Study Identification

Unique Protocol Identification Number
NCT03466112
Brief Title
Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia
Official Title
Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Completed
Study Start Date
June 2016 (Actual)
Primary Completion Date
December 2021 (Actual)
Study Completion Date
December 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ludwig-Maximilians - University of Munich
Collaborators
RWTH Aachen University, Charite University, Berlin, Germany, Heinrich-Heine University, Duesseldorf, Central Institute of Mental Health, Mannheim

4. Oversight

5. Study Description

Brief Summary
The study investigates the efficacy of aerobic exercise on cognitive performance and brain plasticity in schizophrenia.
Detailed Description
This multi-center, two-arm, parallel-group, randomized placebo-controlled add-on clinical trial investigates the efficacy of aerobic exercise on cognitive performance and brain plasticity in schizophrenia. The aim is the enhancement of recovery with the use of 26 weeks of continuos endurance training (aerobic exercise) with stationary bicycles or a balance and tone program consisting of exercises for flexibility, core strength, balance and relaxation. Followed by a follow-up period of 26 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
exercise

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
180 (Actual)

8. Arms, Groups, and Interventions

Arm Title
endurance training
Arm Type
Experimental
Arm Description
endurance training with stationary bicycles
Arm Title
balance and tone program
Arm Type
Active Comparator
Arm Description
flexibility, core strength, balance, relaxation
Intervention Type
Other
Intervention Name(s)
endurance training
Other Intervention Name(s)
aerobic exercise
Intervention Description
endurance training with stationary bicycles
Intervention Type
Other
Intervention Name(s)
balance and tone program
Intervention Description
flexibility, core strength, balance, relaxation
Primary Outcome Measure Information:
Title
all-cause discontinuation
Description
Reason of study discontinuation will be identified. The all-cause-discontinuation questionnaire will be called up 9 times from baseline up to 12 months (compare time frame) including 26 weeks of intervention and 26 weeks follow up period. Reasons are defined as (1) relevant worsening of clinical symptoms (PANSS total score above 75 on cancerous visits for more than 14 days. (2) failure to take the prescribed medication for more than 14 days. (3) Failure to comply scheduled study or diagnostic appointments for more than 6 weeks (4) Patient unavailability despite extensive efforts of the treatment team (5) Withdrawal of patient consent (6) Clinician discontinuation.
Time Frame
12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
Secondary Outcome Measure Information:
Title
improvement in neurocognition (VLMT)
Description
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Verbal Learning and Memory Test (VLMT).
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
improvement in neurocognition (DSST)
Description
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using a test of verbal declarative episodic memory, the Digit Symbol Substitution Test (DSST).
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
improvement in neurocognition (TMT)
Description
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Trail Making Test A and B (TMT) as a test of executive functions, quick visual comprehension, attention, and processing speed.
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
improvement in neurocognition (B-CATS)
Description
The partial aspect of verbal fluid from the letter Cognitive Assessment Tool for Schizophrenia (B-CATS) is also used in the neuropsychological investigation at the main measurement times (at baseline, day 98, day 182 and day 365).
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
improvement in neurocognition (MASC)
Description
As part of the measurement of cognitive performance during the screening phase and at the main measurement times (at baseline, day 98, day 182 and day 365), patients and control subjects will be tested using the Facial Affect Recognition (AOP) and Theory of Mind methods. These are tasks using the Movie for the Assessment of Social Cognition (MASC).
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
improvement in psychopathology (PANSS)
Description
The assessment of psychopathology on the basis of a patient interview takes place at all main measurement times. At baseline, day 98, 182 and day 365. The PANSS uses a standard procedure for assessing schizophrenia symptoms, which measures the severity of individual symptoms as well as the various symptom subgroups of positive and negative symptoms and general psychopathology.
Time Frame
12 months (At baseline, day 98, 182 and day 365)
Title
improvement in psychopathology (CGI)
Description
The Clinical Global Impression Scale (CGI) assesses the overall symptom severity and response to interventions or therapies for psychiatric conditions to assess the effectiveness of the measures applied. It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.
Time Frame
12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
Title
improvement in psychopathology (SOFAS)
Description
The Social and Occupational Functioning Assessment Scale (SOFAS) estimates social and professional performance. It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.
Time Frame
12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
Title
improvement in psychopathology (GAF)
Description
The Social Assessment of Functioning Scale (GAF) also estimates social and professional performance. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
Time Frame
12 months (At baseline, day 98, 182 and day 365)
Title
improvement in psychopathology (BSI-53)
Description
The Brief Symptom Inventory (BSI-53) records the symptoms using 53 items. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
Time Frame
12 months (At baseline, day 98, 182 and day 365)
Title
improvement in psychopathology (CDSS)
Description
The Calgary Depression Scale for Schizophrenia (CDSS) measures suicidality and severity of depressive symptoms. It will be called up 9 times from baseline up to 12 months: At baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365.
Time Frame
12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
Title
improvement in social and occupational functioning (UPSA-B)
Description
The University of California San Diego Performance-based Skills Assessment (UPSA-B) will be used to assess the day-to-day functioning of patients with schizophrenia in the household, communications, finance, transportation, and leisure activities role play situations. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
improvement in social and occupational functioning (FROGS)
Description
Functional Remission of General Schizophrenia (FROGS) is used as a tool to measure changes in functional levels. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
improvement in social and occupational functioning (PSP)
Description
The Personal and Social Performance Scale (PSP) is also a tool to measure changes in functional levels. It takes place at all main measurement times. At baseline, day 98, 182 and day 365.
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
improvement in quality of life
Description
Only at the beginning and end of the intervention, and after one year, is the World Health Organization's Quality of Life Questionnaire (WHOQOL-Bref) used to record quality of life (The WHOQOL Group, 1998).
Time Frame
12 months (at baseline, day 182 and day 365)
Title
improvement in body mass index (BMI)
Description
Also, the body height (in meter) and weight (in kg) of the study participants are measured. Thereupon the BMI is calculated from the body weight (kg) divided by the square of the height (m2). The unit of BMI is kg / m2.
Time Frame
12 months (at baseline, day 14, 68, 98, 140, 182, 196, 273 and day 365)
Title
change of connectivity analysis (MRI of the brain)
Description
At four time points, just prior to initiation of V1, V4, V6 after the end of the intervention and at V9 after the follow-up period of 6 months, structural and functional MRI (fMRI) examinations are performed on a 3 Tesla whole-body MR scanner in patients and healthy control subjects (Siemens) made. The findings are compared with data from healthy controls and non-diseased first-degree relatives of patients with schizophrenia who have been evaluated in other BMBF-funded studies ("MooDS", "IntegraMent"). In addition, cross-sectional comparisons (TAU + Exercise vs. TAU + BKGT) and progress measurements to characterize treatment effects are planned. The measurements are divided into 2 appointments to reduce the burden on patients and subjects by the measurement time.
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
change of volumes of brain regions (MRI)
Description
First, structural measurements (T1 sequence, duration: approx. 5 minutes) and investigations of the fiber connections in the brain by means of diffusion-weighted imaging (DTI, duration: approx. 10 minutes) are carried out.
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
change of brain function (MRI)
Description
By means of fMRI, the tasks resting activity, working memory, episodic memory, reward processing, social perspective takeover, emotion processing as well as ability to inhibit are to be investigated with already well pre-examined tasks. A function measurement is performed at rest without stimulation (rsMRT), which provides information on the functional networking of different brain regions at rest (duration: approx. 5 minutes). There are also three fMRI surveys that record brain activity during simple psychological tasks. - The ability to inhibit (prefrontal cortex, anterior cingulate gyrus) is examined by means of a so-called flanker task. This is to respond to a specific target stimulus, which is surrounded by either the same (congruent) or by distracting (incongruent) stimuli. - Duration: 11 minutes
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
improvement of endurance capacity
Description
As part of the sports medical stress test, the determination of endurance performance in patients and control subjects takes place. For this examination, like in training, finder bike use and measurements of heart rate, lactate concentration and exertion sensation are performed. The ergometry is carried out as a Vita maxima examination, so it ends when the subjects can not or do not want to keep pedaling or when the termination criteria according to Steinacker & Liu (2002) occur. From the examination, various submaximal and maximal parameters can be determined, have the validity for endurance performance and the training intensity can be determined. The examination is carried out under standardized and safe conditions and after a detailed medical history and physical examination to exclude contraindications. Activity meters are used to control the physical activity of study participants outside the study intervention.
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
change of medication and attitude of the study participants to therapy (DAI)
Description
Also, the attitude of the study participants to therapy and medication is recorded. For this, the Drug Attitude Inventory (DAI) is used. Is takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
change of medication and attitude of the study participants to therapy (SES)
Description
The Service Engagement Scale (SES), which assesses accessibility, cooperation, help seeking and adherence, is used. It takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
improvement in metabolic parameters
Description
The laboratory diagnostic measures include a laboratory blood test, with evaluation of blood lipid levels, the C-reactive protein, glycohemoglobin (HBA1c). It takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
urine (testing pregnancy and drug abuse)
Description
Examination of the urine at baseline excludes pregnancy and drug abuse.
Time Frame
baseline
Title
gene expression
Description
Investigation of gene expression takes place at baseline.
Time Frame
baseline
Title
change of genome-wide epigenetics
Description
Investigation of genome-wide epigenetics takes place at the main measurement times (at baseline, day 98, day 182 and day 365).
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
change of proteomics
Description
Investigation of proteomics at the main measurement times (at baseline, day 98, day 182 and day 365).
Time Frame
12 months (at baseline, day 98, day 182 and day 365)
Title
change of BDNF level
Description
Investigation of BDNF levels at the main measurement times (at baseline, day 98, day 182 and day 365).
Time Frame
12 months (at baseline, day 98, day 182 and day 365)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Informed consent given by the subject; DSM-IV-TR diagnosis of schizophrenic psychosis (295.10-30, 295.90); age 18 to 65 years, male or female; PANSS at baseline: total score ≤ 75, proper contraception in female patients of childbearing potential; treatment with one or two antipsychotics in a stable dose of at least two weeks, body mass index between 18 and 40. Exclusion Criteria: Lack of accountability; positive urine drug-screening for illicit drugs at screening (except benzodiazepines); serious suicidal risk at screening visit; other relevant interferences of axis 1 according to diagnostic evaluation (MINI); other relevant neurological or other medical disorders; pregnancy or lactation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter G. Falkai, Prof. Dr.
Organizational Affiliation
LMU Munich
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ludwig-Maximilians-University of Munich
City
Munich
State/Province
Bavaria
ZIP/Postal Code
80366
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
36114184
Citation
Maurus I, Roell L, Keeser D, Papazov B, Papazova I, Lembeck M, Roeh A, Wagner E, Hirjak D, Malchow B, Ertl-Wagner B, Stoecklein S, Hasan A, Schmitt A, Meyer-Lindenberg A, Falkai P. Fitness is positively associated with hippocampal formation subfield volumes in schizophrenia: a multiparametric magnetic resonance imaging study. Transl Psychiatry. 2022 Sep 16;12(1):388. doi: 10.1038/s41398-022-02155-x.
Results Reference
derived
PubMed Identifier
35488054
Citation
Roell L, Maurus I, Keeser D, Karali T, Papazov B, Hasan A, Schmitt A, Papazova I, Lembeck M, Hirjak D, Sykorova E, Thieme CE, Muenz S, Seitz V, Greska D, Campana M, Wagner E, Loehrs L, Stoecklein S, Ertl-Wagner B, Poemsl J, Roeh A, Malchow B, Keller-Varady K, Meyer-Lindenberg A, Falkai P. Association between aerobic fitness and the functional connectome in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2022 Oct;272(7):1253-1272. doi: 10.1007/s00406-022-01411-x. Epub 2022 Apr 30.
Results Reference
derived
PubMed Identifier
32748261
Citation
Maurus I, Hasan A, Schmitt A, Roeh A, Keeser D, Malchow B, Schneider-Axmann T, Hellmich M, Schmied S, Lembeck M, Keller-Varady K, Papazova I, Hirjak D, Topor CE, Walter H, Mohnke S, Vogel BO, Wolwer W, Schneider F, Henkel K, Meyer-Lindenberg A, Falkai P. Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial. Eur Arch Psychiatry Clin Neurosci. 2021 Mar;271(2):315-324. doi: 10.1007/s00406-020-01175-2. Epub 2020 Aug 3. Erratum In: Eur Arch Psychiatry Clin Neurosci. 2021 Oct;271(7):1405-1406.
Results Reference
derived

Learn more about this trial

Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia

We'll reach out to this number within 24 hrs